| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5547f741b25666fc4ae5195cf71a979b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6bf42ec0e2f3fddbf85941cc57174057 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2014-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11fe704c2f27a21f40f3b9c80f86f676
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11f1d6ecc7c00ec60dd8ad9f7ef1fa61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_540c99c974d4f4c9da2aec7e54a63127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33283bfbfa9b5d65cf70f3dcd7f6b32a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e4bc3539483aedb271ae81476383aba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cfc9ac629de452fcba3a8f8b98d2e30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a5f0b277eb8b1b54986d8fed9e9a9a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69764ff99728b68071d05f2f6d8ff2d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12310736bea70c634e92ae9169a5ddfe |
| publicationDate |
2015-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2015051011-A |
| titleOfInvention |
Cancer marker, cancer evaluation method and evaluation reagent using the same |
| abstract |
The present invention provides a novel cancer marker for evaluating the onset, preclinical stage, clinical stage or prognosis of a subject's cancer, and an evaluation method using the same. A cancer marker excluding breast cancer is used as a cancer marker containing at least one miRNA of hsa-miR-92 and hsa-miR-494. The method for evaluating the possibility of cancer other than breast cancer includes a cancer marker detection step of detecting the expression level of a cancer marker in a biological sample collected from a subject, wherein the cancer marker comprises hsa-miR-92 and hsa-. A cancer marker comprising at least one miRNA of miR-494. [Selection] Figure 3 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021124455-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021125105-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7297902-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2021125105-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019117270-A1 |
| priorityDate |
2008-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |